Evropská unie - islandština - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - krabbamein, lungnakrabbamein - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

Island - islandština - LYFJASTOFNUN (Icelandic Medicines Agency)

alk-abelló a/s - betula verrucosa - stungulyf, dreifa

Island - islandština - LYFJASTOFNUN (Icelandic Medicines Agency)

alk-abelló a/s - kattahár - stungulyf, dreifa

Island - islandština - LYFJASTOFNUN (Icelandic Medicines Agency)

alk-abelló a/s - dermatophagoides pteronyssinus - stungulyf, dreifa

Island - islandština - LYFJASTOFNUN (Icelandic Medicines Agency)

alk-abelló a/s - hundahár - stungulyf, dreifa

Island - islandština - LYFJASTOFNUN (Icelandic Medicines Agency)

alk-abelló a/s - phleum pratense - stungulyf, dreifa

Evropská unie - islandština - EMA (European Medicines Agency)

bayer ag - larotrectinib súlfat - kvið Æxli - Æxlishemjandi lyf - vitrakvi eitt og sér er ætlað til meðferð við fullorðna og börn sjúklinga með solid æxli að sýna taugavaxtar týrósín viðtaka nt (ntrk) gene samruna,sem hafa sjúkdóm sem er á staðnum háþróaður, sjúklingum eða hvar skurðaðgerð er líklegt að niðurstöðu í alvarlegum sjúkdómum, oghver hef enga fullnægjandi meðferð valkosti.

Island - islandština - LYFJASTOFNUN (Icelandic Medicines Agency)

fresenius kabi ab - ceftriaxonum dínatríum - stungulyfs-/innrennslisstofn, lausn - 1 g

Island - islandština - LYFJASTOFNUN (Icelandic Medicines Agency)

fresenius kabi ab - ceftriaxonum dínatríum - innrennslisstofn, lausn - 2 g

Evropská unie - islandština - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.